High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer.
Lejeune
F J
FJ
Fondation du Centre Pluridisciplinaire d'Oncologie, CHUV, Lausanne, Switzerland.
D000818:Animals; D010478:Chemotherapy, Cancer, Regional Perfusion; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage; D008545:Melanoma / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage; D051379:Mice; D008954:Models, Biological; D011994:Recombinant Proteins / Q000008:administration & dosage; D012509:Sarcoma / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D008558:Melphalan